Food Marketing, Advertising, and Promotion Essentials: Ensuring Claims Compliancy and Meeting Substantiation Standards Relative to Health, Nutrition, Structure, and Function

July 22, 2025 4:00pm

Adam Ekonomon
Vice President and Deputy General Counsel, Marketing & Advertising
The J.M. Smucker Company

Kristen R. Klesh
Partner
Loeb & Loeb LLP

Andrew Lustigman
Partner
Olshan, Frome, Wolosky LLP

  • Examining the relationship between the food product label and advertising and promotion
  • Differentiating “claims made” from “claims substantiated”
  • Understanding what you can and cannot say in food advertising and promotion
  • Overview of food product claims and the regulatory requirements for making each:
    • Nutrient and health
    • Structure/function – dietary supplements vs. conventional foods
    • Mental performance and focus
    • Disease
    • Comparative
    • Calories/ingredients
  • Distinguishing FDA and FTC jurisdiction and authority relative to claims substantiation in food advertising and promotion
    • Identifying proofs required to substantiate product claims under FDA and FTC expectations
      • Clinical studies
      • Scientific evidence and testing
      • Consumer surveys
      • Taste and internal expert panels
      • Market research firms
      • Avoiding puffery
  • When social media and websites can be viewed as a means of advertising and promotion
  • Understanding what recent enforcement actions reveal about food and beverage marketing and advertising vulnerabilities
  • Monitoring of food advertising by National Advertising Division of the Better Business Bureau (NAD)
    • Children’s Advertising Review Unit (CARU)
  • Exploring Lanham Act challenges relative to false and misleading claims for competitor products
  • Assessing when health claims for a food product that have been cleared through FDA’s pre-market clearance procedures can be deemed unauthorized under the FD&C Act
  • Identifying circumstances under which disease prevention claims for a food product may relegate that product to the status of an unapproved new drug